Inovio reports Q1 EPS (51c), consensus (74c)

Reports Q1 revenue $65,343, consensus $10,000. As of March 31, 2025, cash, cash equivalents and short-term investments were $68.4M, compared to $94.1M, as of December 31, 2024. “I’m pleased to confirm that we remain on track to submit our BLA for INO-3107 this year. As previously stated, our goal is to begin rolling submission in mid-2025, complete the submission in the second half of 2025 and receive file acceptance from the FDA by year end. If we receive priority review, it could allow for a PDUFA date in mid-2026,” said Jacqueline Shea, INOVIO’s (INO) President and CEO. “We continue to focus our efforts and resources toward bringing this important product candidate to patients eager for a non-surgical therapeutic option to treat this devastating disease. Based on market research, we believe INO-3107 could be the preferred product for patients and providers, if approved. Beyond INO-3107, we are excited about the recently announced promising data from a proof-of-concept Phase 1 clinical trial with our next-generation DMAb technology, as well as the potential of our entire DNA medicines pipeline.”